Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Underreporting of prognostic factors in real-world studies for bispecifics in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Marin Xavier, Eva Baginska, Monika Jun, Tychell Branchcomb, Alex Mutebi, David Tybor, Anthony Wang, Kristen Cribbs, Betsy Lahue

Blood (2025) 146 (Supplement 1): 4481.

https://doi.org/10.1182/blood-2025-4481

Published: 2025

Journal Articles

Effectiveness of epcoritamab in a heterogeneous population with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) including post-chimeric antigen receptor T-cell therapy (CAR T) patients: Insights from the real-world epcoritamab patient characteristics and outcomes research (Real-EPCOR) study

Amir Ali, Pallawi Torka, Yucai Wang, Tara Graff, Erin Mulvey, Yumeng Zhang, Monika Jun, Abualbishr Alshreef, Alex Mutebi, Anthony Wang, David Tybor, Lynn Huynh, Angela Lax, Tychell Branchcomb, Mei Sheng Duh, Javier Munoz, Muhamad Alhaj Moustafa, Nausheen Ahmed

Blood (2025) 146 (Supplement 1): 8075.

https://doi.org/10.1182/blood-2025-8075

Published: 2025

Journal Articles

Operational efficiencies and cost savings of using one bispecific antibody FDA-approved for both R/R 3L+ DLBCL and FL

Tara Graff, Savreet Bains Chawla, Monika Jun, Nicole Heaps, Abualbishr Alshreef, David Tybor, Nadine Zawadzki, Kathryn Spurrier, Jason Shafrin

Blood (2025) 146 (Supplement 1): 7942.

https://doi.org/10.1182/blood-2025-7942

Published: 2025